{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:51:56Z","timestamp":1761875516130,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista de Psiquiatr\u00eda y Salud Mental (English Edition)"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.rpsmen.2021.08.002","type":"journal-article","created":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T07:13:17Z","timestamp":1629961997000},"page":"157-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of aripiprazole and risperidone effectiveness in first episode non-affective psychosis: Rationale and design of a prospective, randomized, 3-phase, investigator-initiated study (PAFIP-3)"],"prefix":"10.1016","volume":"14","author":[{"given":"Mayoral-van","family":"Son J.","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"G\u00f3mez-Revuelta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Ayesa-Arriola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"V\u00e1zquez-Bourg\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor Ortiz-Garc\u00eda de la","family":"Foz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Ruiz-Veguilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalia","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Tordesillas-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Seti\u00e9n-Suero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedicto","family":"Crespo-Facorro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpsmen.2021.08.002_bib0145","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1176\/appi.ajp.2015.15050632","article-title":"Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH RAISE early treatment program","volume":"173","author":"Kane","year":"2016","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.rpsmen.2021.08.002_bib0150","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyaa004","article-title":"Antipsychotic treatment effectiveness in first episode of psychosis: PAFIP 3-year follow-up randomized clinical trials comparing haloperidol, olanzapine, risperidone, aripiprazole, quetiapine, and ziprasidone","author":"Gomez-Revuelta","year":"2020","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.rpsmen.2021.08.002_bib0155","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40120-016-0050-8","article-title":"Current data on and clinical insights into the treatment of first episode nonaffective psychosis: a comprehensive review","volume":"5","author":"Crespo-Facorro","year":"2016","journal-title":"Neurol Ther"},{"key":"10.1016\/j.rpsmen.2021.08.002_bib0160","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.rpsmen.2021.08.002_bib0165","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S2215-0366(18)30252-9","article-title":"Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study","volume":"5","author":"Kahn","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.rpsmen.2021.08.002_bib0170","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4088\/JCP.v69n0114","article-title":"Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study","volume":"69","author":"Perkins","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.rpsmen.2021.08.002_bib0175","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/jcp.0b013e3180d0a6d4","article-title":"Early use of clozapine for poorly responding first-episode psychosis","volume":"27","author":"Agid","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.rpsmen.2021.08.002_bib0180","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1192\/bjp.bp.111.105833","article-title":"Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation","volume":"201","author":"Howes","year":"2012","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.rpsmen.2021.08.002_bib0185","first-page":"281","article-title":"Clozapine as treatment of first choice in first psychotic episodes. What do we know?","volume":"40","author":"Vera","year":"2012","journal-title":"Actas Esp Psiquiatr"},{"key":"10.1016\/j.rpsmen.2021.08.002_bib0190","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/YIC.0000000000000086","article-title":"Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia","volume":"30","author":"Ucok","year":"2015","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.rpsmen.2021.08.002_bib0195","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.rpsm.2018.02.005","article-title":"Pattern of use of clozapine in Spain. Variability and under-prescription","volume":"12","author":"Sanz-Fuentenebro","year":"2019","journal-title":"Rev Psiquiatr Salud Ment"},{"key":"10.1016\/j.rpsmen.2021.08.002_bib0200","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.psychres.2019.03.029","article-title":"Psychiatrists\u2019 attitude towards the use of clozapine in the treatment of refractory schizophrenia: a nationwide survey","volume":"275","author":"Daod","year":"2019","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.rpsmen.2021.08.002_bib0205","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.schres.2018.02.054","article-title":"Clozapine use in early psychosis","volume":"199","author":"Thien","year":"2018","journal-title":"Schizophr Res"},{"year":"2005","series-title":"Programa asistencial para las fases iniciales de psicosis de Cantabria (PAFIP)","author":"Crespo-Facorro","key":"10.1016\/j.rpsmen.2021.08.002_bib0210"},{"key":"10.1016\/j.rpsmen.2021.08.002_bib0215","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1751-7893.2008.00074.x","article-title":"Epidemiological factors associated with treated incidence of first-episode non-affective psychosis in Cantabria: insights from the Clinical Programme on Early Phases of Psychosis","volume":"2","author":"Pelayo-Teran","year":"2008","journal-title":"Early Inter Psychiatry"},{"key":"10.1016\/j.rpsmen.2021.08.002_bib0220","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.4088\/JCP.v67n1004","article-title":"A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis","volume":"67","author":"Crespo-Facorro","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.rpsmen.2021.08.002_bib0225","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00406-015-0667-0","article-title":"Diagnosis and neurocognitive profiles in first-episode non-affective psychosis patients","volume":"266","author":"Ayesa-Arriola","year":"2016","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.rpsmen.2021.08.002_bib0230","article-title":"Structured Clinical Interview for DSM-IV-TR Axis I Disorders Research Version Patient Edition with Psychotic Screen (SCID-I\/P)","author":"First","year":"2002","journal-title":"Biometrics Res"},{"key":"10.1016\/j.rpsmen.2021.08.002_bib0235","doi-asserted-by":"crossref","unstructured":"Guy, W.E.A.M.f.P.R.E.A.M. ECDEU Assessment Manual for Psychopharmacology: Revised. ECDEU Assessment Manual; 1976.","DOI":"10.1037\/e591322011-001"},{"key":"10.1016\/j.rpsmen.2021.08.002_bib0240","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol Rep"},{"year":"1984","series-title":"The Scale for the Assessment of Positive Symptoms (SAPS)","author":"Andreasen","key":"10.1016\/j.rpsmen.2021.08.002_bib0245"},{"year":"1983","series-title":"The Scale for the Assessment of Negative Symptoms (SANS)","author":"Andreasen","key":"10.1016\/j.rpsmen.2021.08.002_bib0250"},{"key":"10.1016\/j.rpsmen.2021.08.002_bib0255","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1192\/S0007125000292581","article-title":"Assessing depression in schizophrenia: the Calgary depression scale","volume":"163","author":"Addington","year":"1993","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.rpsmen.2021.08.002_bib0260","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.rpsmen.2021.08.002_bib0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"76","author":"Lingj\u00e6rde","year":"1987","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.rpsmen.2021.08.002_bib0270","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"Suppl. 212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.rpsmen.2021.08.002_bib0275","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.rpsmen.2021.08.002_bib0280","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing","volume":"167","author":"Gardner","year":"2010","journal-title":"Am J Psychiatry"}],"container-title":["Revista de Psiquiatr\u00eda y Salud Mental (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S217350502100042X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S217350502100042X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:42:43Z","timestamp":1761874963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S217350502100042X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S217350502100042X"],"URL":"https:\/\/doi.org\/10.1016\/j.rpsmen.2021.08.002","relation":{},"ISSN":["2173-5050"],"issn-type":[{"type":"print","value":"2173-5050"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of aripiprazole and risperidone effectiveness in first episode non-affective psychosis: Rationale and design of a prospective, randomized, 3-phase, investigator-initiated study (PAFIP-3)","name":"articletitle","label":"Article Title"},{"value":"Revista de Psiquiatr\u00eda y Salud Mental (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpsmen.2021.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 SEP y SEPB. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}